^
    2d
    Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    Lynparza (olaparib) • BMS‐986504
    2d
    Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working (clinicaltrials.gov)
    P2/3, N=73, Active, not recruiting, National Cancer Institute (NCI) | N=190 --> 73 | Trial completion date: Mar 2030 --> Jan 2027
    Enrollment change • Trial completion date
    |
    Lynparza (olaparib) • temozolomide • pazopanib • Yondelis (trabectedin)
    3d
    Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. (PubMed, J Clin Invest)
    PARP inhibition with olaparib increased residual γH2AX/53BP1 foci post-irradiation in ERG+ cells, indicating enhanced radiosensitization...These findings suggest that ERG expression promotes dependency on PARP1-EJ, rendering ERG+ PCa more susceptible to PARP inhibition. Combining PARP inhibitors with RT may offer a tumor-selective radiosensitization for ERG+ PCa patients.
    Journal • PARP Biomarker
    |
    ERG (ETS Transcription Factor ERG) • TMPRSS2 (Transmembrane serine protease 2) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • XRCC1 (X-Ray Repair Cross Complementing 1) • LIG3 (DNA Ligase 3)
    |
    TMPRSS2-ERG fusion
    |
    Lynparza (olaparib)
    4d
    Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Pamela Munster | Trial completion date: Feb 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2)
    |
    PALB2 mutation • CHEK2 mutation
    |
    Lynparza (olaparib) • Inqovi (decitabine/cedazuridine)
    4d
    Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia. (PubMed, Br J Haematol)
    With known roles for KDM4A family members in deoxyribonucleic acid (DNA) damage response repair pathways, inhibition of KDM4A increased accrual of double strand DNA breaks. Hence, we demonstrated KDM4i sensitisation of leukaemia cells to inhibitors of DNA damage pathways such as poly-ADP ribose polymerase (PARP) inhibitor, olaparib, suggesting future clinical evaluation of KDM4A and other key components in DNA damage/response signalling pathways as potential therapeutic vulnerabilities in AML.
    Journal • Tumor mutational burden • PARP Biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    Lynparza (olaparib)
    6d
    Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. (PubMed, Sci Rep)
    However, the randomized phase III POLO trial, upon which this standard is based, did not demonstrate an improved overall survival in patients who received olaparib compared to those who received placebo, highlighting the need for new therapeutic approaches...The model demonstrated high sensitivity to cisplatin plus gemcitabine, but limited efficacy of PARPi monotherapy...The addition of anti-PD1 treatment to PARPi maintenance enhanced tumor regression and prolonged overall survival. These findings provide preclinical support for ongoing clinical trials investigating immunotherapy with PARPi as a maintenance strategy in homologous recombination-deficient PDAC.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • CDX2 (Caudal Type Homeobox 2)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • cisplatin • gemcitabine
    7d
    Apigenin modulates cell survival pathways and restores olaparib sensitivity in high-grade serous ovarian cancer cells. (PubMed, Taiwan J Obstet Gynecol)
    API suppresses HGSOC progression by inducing apoptosis, arresting the cell cycle, and modulating survival pathways. It also restores olaparib sensitivity in resistant cells, supporting its potential as an adjuvant therapy to enhance olaparib efficacy in combination treatments.
    Journal • PARP Biomarker
    |
    CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CCNB1 (Cyclin B1)
    |
    Lynparza (olaparib)
    7d
    Drastic Response to Olaparib in a Patient With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA2 Alterations and Near-Threshold Tumor Mutational Burden. (PubMed, IJU Case Rep)
    Over 3 months, MRI showed further regression of the primary lesion and nodal disease, and PSA and SCC decreased. In metastatic CRPC harboring a BRCA2 mutation and near-threshold TMB, olaparib produced clear radiological and serological responses.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset)
    |
    TMB-H
    |
    Lynparza (olaparib)
    9d
    Pembrolizumab Plus Olaparib in LA-HNSCC (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Nov 2030 | Trial primary completion date: Oct 2025 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin
    9d
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=266, Recruiting, Beijing Tide Pharmaceutical Co., Ltd
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • MSI-H/dMMR • BRAF mutation • NRAS mutation • RAS mutation • RET mutation • MET mutation
    |
    Lynparza (olaparib) • topotecan • Andewei (benmelstobart)
    9d
    TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. (PubMed, J Clin Oncol)
    Olaparib is active in pts with MBC with gPALB2m and sBRCAm, significantly expanding the population of pts with breast cancer likely to benefit from PARP inhibitors beyond gBRCA1/2m carriers.
    P2 data • Journal • BRCA Biomarker • PARP Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset)
    |
    ER positive • HER-2 negative • PALB2 mutation • EGFR positive • BRCA mutation
    |
    Lynparza (olaparib)
    9d
    Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone. (PubMed, J Clin Med)
    We conclude that the optimal use of PARP inhibitors, PSMA-targeted RLT, and ARPIs requires a personalized strategy guided by molecular profiling, functional imaging, prior treatment exposure, and safety considerations. This clinically focused overview aims to support evidence-based decision-making in an increasingly complex treatment landscape.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • AR (Androgen receptor) • HRD (Homologous Recombination Deficiency)
    |
    FOLH1 positive
    |
    Lynparza (olaparib) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)